



Request No.

2020-00798-FOIA-OS

American Oversight v. U.S. Dep't. Health and Human Services et al., 20-cv-1343

July 13, 2020

Sent via e-mail

Ms. Melanie Sloan

Senior Advisor

American Oversight

1030 15th Street, N.W., Suite B255

Washington, DC 20005

foia@Americanoversight.org

Dear Ms. Sloan:

This letter is the Department of Health and Human Services' (HHS) first interim response to your March 26, 2020 Freedom of Information Act (FOIA) request. Specifically, you requested the following records from February 1, 2020, to the date the search is conducted:

All email communications (email messages, email attachments, complete email chains, calendar invitations, and attachments thereto) between (1) the agency officials specified below and (2) Rep. Mark Meadows, including any personal email addresses, as well as official house.gov email addresses attributed to Rep. Meadows, and anyone serving on his staff, including Chief of Staff Ben Williamson (ben.williamson@mail.house.gov), Scheduler Kate Morgan (kate.morgan@mail.house.gov), or Legislative Director Eric Heigis (eric.heigis@mail.house.gov).

Department of Health and Human Services i. Secretary Alex Azar and anyone communicating on his behalf, such as a scheduler or assistant ii. Anyone serving in the capacity of Chief of Staff or Executive Secretary iii. Anyone serving in the capacity of White House Liaison or White House Advisor, and their deputies iv. Anyone serving in the capacity of Director of Legislative Affairs.

The Department has processed 11 pages of potentially responsive records captured in the agency's search for FOIA request 2020-00798-FOIA-OS.

After a careful review of these pages, I have determined to release 7 pages to you in their entirety,

Page 2 of 2

Request No.

2020-00798-FOIA-OS

American Oversight v. U.S. Dep't. Health and Human Services et al., 20-cv-1343

and I am further releasing 2 pages in part, with portions redacted, pursuant to Exemption (b)(6) of the FOIA (5 U.S.C. §§ (b)(6)). Finally, 2 pages are still under consideration pending consultation by the Administration for Children and Families.

FOIA exemption (b)(6) permits a Federal agency to withhold information and records about individuals in "personnel and medical files and similar files, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy." The definition of "similar files" has historically been broadly interpreted to include a wide variety of files, and the United States Supreme Court has held that Congress intended the term "similar files" to be interpreted broadly, rather than narrowly. I have analyzed these records and find they meet the threshold requirement of this exemption. Additionally, I have reviewed and weighed the public interest in disclosure of this information against the privacy interest in nondisclosure, and found that the privacy interest outweighs the public's interest in disclosure.

Should you have questions or concerns regarding the Department's response and/or the processing of your request, any such issues should be communicated to your legal counsel and Department of Justice Attorney representing the Department in this matter.

Sincerely yours,



Brandon J. Gaylord
Director
FOI/Privacy Act Division

Enclosure: 09 pages

From:	Baxter, Michael <mbaxter@aphanet.org>
To:	(b)(6)@ovp.eop.gov>; Birx, Deborah (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d15204375cb04b919b9e33618ff62fb3-Birx, Debor>; Azar, Alex (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd4875f6a7414810934ed443c7f34740-Azar, Alex>; Harrison, Brian (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d145efc9c35c4865aca6e9d47786b204-Harrison, B>; Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>; Verma, Seema (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e36583cd19bb453997718e4ca9ac8a93-SeemaVermaP>; Kouzoukas, Demetrios (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f4b26cbb0cbd43dd99c01d0862026aa3-KLY4>; <robert.wilkie@va.gov>; <secretary.carson@hud.gov>; Hahn, Stephen (FDA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c0666f41e4514dd3b294a23789487280-stephen.hah>; Lenihan, Keagan (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7aa9d3462c324d65a1da026ba1e76aa5-Lenihan, Ke>; Adams, Jerome (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=184fe51f7350400b8a99dabd65ac0db5-Adams, Jero>; (b)(6)@ostp.eop.gov>; (b)(6)@who.eop.gov>; Redfield, Robert R. (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9ab74a26317547b8a754285d9eaa847c-robert.redf>; Fauci, Anthony (NIH/NIAID) [E] </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=826965b24a314ffca7eddc6e8229aa7-anthony.fau>; (b)(6)@state.gov>; (b)(6)@uscis.dhs.gov>; <joel.szabat@dot.gov>; (b)(6)@nsc.eop.gov>; (b)(6)@who.eop.gov>; (b)(6)@omb.eop.gov>; (b)(6)@who.eop.gov>; (b)(6)@omb.eop.gov>; (b)(6)@who.eop.gov>; Patel, Anita (CDC/DDID/NCIRD/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1281344f1dab4bd28aff1cf48cc25420-Patel, Anit>; (b)(6)@who.eop.gov>; <ben.williamson@mail.house.gov>
CC:	Bernstein, Ilisa <IBernstein@aphanet.org>; Menighan, Tom <TMenighan@APHANET.ORG>; Rothholz, Mitch <MRothholz@APHANET.ORG>; Burns, Anne <ABurns@APHANET.ORG>; Mica, Alicia Kerry <AMica@APHANET.ORG>
Subject:	APhA Recommendations to the President's Coronavirus Task Force to Maximize the Use of Pharmacists to Prevent, Treat, and Respond to Coronavirus.
Date:	2020/03/13 15:46:55
Priority:	Normal
Type:	Note

March 13, 2020

The Honorable Mike Pence
 Vice President
 The White House
 1600 Pennsylvania Avenue, NW
 Washington, DC 20501

RE: APhA Recommendations to the President's Coronavirus Task Force to Maximize the Use of Pharmacists to Prevent, Treat, and Respond to Coronavirus

Dear Vice President Pence:

We are writing to support your efforts and to serve as a resource for the President's Coronavirus Task Force (hereinafter, "Task Force") in assisting both the federal and state governments meet the public health challenges of the coronavirus. APhA has already issued preparedness and prevention guidance for pharmacists, patients and/ or caregivers during the coronavirus pandemic, extending the reach of resources and information provided by Centers for Disease Control ("CDC") and other reputable sources.^[1] Pharmacists are well-positioned to provide information and educational resources related to coronavirus to the public. We can do more.

As President Trump has declared a national public health emergency under the National Emergencies Act and the Secretary of Health and Human Services ("HHS") has declared a public health emergency under Section 319 of the Public Health Service Act, the Secretary is authorized to take additional actions in addition to his regular authorities. Under Section 1135 of the Social Security Act, the HHS Secretary may now temporarily waive or modify certain Medicare, Medicaid, and Children's Health Insurance Program ("CHIP") requirements to ensure that sufficient health care items and services are available to meet the needs of individuals enrolled in Social Security Act programs in the emergency area and time periods. It also allows providers who provide such services in good faith can be reimbursed and exempted from sanctions (absent any determination of fraud or abuse). **Accordingly, APhA urges the Task Force and the HHS Secretary to use the full authority of Section 1135 to maximize the use of pharmacists to prevent, treat, and respond to the coronavirus.** America's pharmacists stand ready and able to provide the patient care services necessary to help meet the public health needs created by the spread of the coronavirus (COVID-19).

APhA represents nearly 60,000 pharmacists, pharmaceutical scientists, student pharmacists, pharmacy technicians, and others interested in improving medication use and advancing patient care. APhA members provide care in all practice settings, including community pharmacies, specialty pharmacies, hospitals, long-term care facilities, community health centers, physician offices, ambulatory clinics, managed care organizations, hospice settings, and the uniformed services. APhA has a track record as a strong partner with HHS, CDC, Food and Drug Administration ("FDA") and other agencies in addressing public health needs of communities such as immunizations, emergency preparedness, substance use disorder/opioids, diabetes and other public health concerns.

See, attached .PDF for full comments and recommendations.

Pharmacists stand ready and able to help. We look forward to working the President's Coronavirus Task Force to intervene and provide meaningful services to meet the public health challenge created by the coronavirus – which can serve as an effective mechanism to combat additional public health emergencies in the future. If you have any questions, or if we can be of any assistance, please do not hesitate to contact Michael Baxter, Director of Regulatory Affairs, at mbaxter@aphanet.org or by phone at (202) 429-7538.

Michael Baxter

Director, Regulatory Affairs

American Pharmacists Association

2215 Constitution Avenue, NW

Washington, DC 20037-2985

800-237-APhA (2742)

Phone: (202) 429-7538

mbaxter@aphanet.org

<https://protect2.fireeye.com/url?k=82f99c34-deadb51f-82f9ad0b-0cc47a6d17cc-d9b4a8ee1bdebe6f&u=http://www.pharmacist.com/>

[1]

APhA Issues Preparedness and Prevention Guidance During Coronavirus Pandemic. Press Release. March 6, 2020, available at: <https://protect2.fireeye.com/url?k=5c763c10-0022153b-5c760d2f-0cc47a6d17cc-1e6c22d7b95f63f1&u=https://www.pharmacist.com/press-release/apha-issues-preparedness-and-prevention-guidance-during-coronavirus-pandemic>

Sender:	Baxter, Michael <mbaxter@aphanet.org>
	(b)(6)@ovp.eop.gov>; Birx, Deborah (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d15204375cb04b919b9e33618ff62fb3-Birx, Deborah>; Azar, Alex (OS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=cd4875f6a7414810934ed443c7f34740-Azar, Alex>; Harrison, Brian (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d145efc9c35c4865aca6e9d47786b204-Harrison, B>; Kadlec, Robert (OS/ASPR/IO) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a182eda693d040d3832bae6efcf7a255-Kadlec, Rob>; Verma, Seema (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e36583cd19bb453997718e4ca9ac8a93-SeemaVermaP>; Kouzoukas, Demetrios (CMS/OA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=f4b26cbb0cbd43dd99c01d0862026aa3-KLY4>; <robert.wilkie@va.gov>; <secretary.carson@hud.gov>; Hahn, Stephen (FDA) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c0666f41e4514dd3b294a23789487280-stephen.hah>; Lenihan, Keagan (HHS/IOS) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=7aa9d3462c324d65a1da026ba1e76aa5-Lenihan, Ke>; Adams, Jerome (HHS/OASH) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=184fe51f7350400b8a99dabd65ac0db5-Adams, Jero>; (b)(6)@ostp.eop.gov>;
Recipient:	(b)(6)@who.eop.gov>; Redfield, Robert R. (CDC/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9ab74a26317547b8a754285d9eaa847c-robert.redf>; Fauci, Anthony (NIH/NIAID) [E] </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=826965b24a314ffca7eddc6b6e8229aa7-anthony.fau>; (b)(6)@state.gov>; (b)(6)@uscis.dhs.gov>; <joel.szabat@dot.gov>; (b)(6)@nsc.eop.gov>; (b)(6)@who.eop.gov>; (b)(6)@omb.eop.gov>; (b)(6)@who.eop.gov>; (b)(6)@omb.eop.gov>; (b)(6)@who.eop.gov>; Patel, Anita (CDC/DDID/NCIRD/OD) </o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=1281344f1dab4bd28aff1cf48cc25420-Patel, Anit>; (b)(6)@who.eop.gov>; <ben.williamson@mail.house.gov>; Bernstein, Ilisa <IBernstein@aphanet.org>; Menighan, Tom <TMenighan@APHANET.ORG>; Rothholz, Mitch <MRothholz@APHANET.ORG>; Burns, Anne <ABurns@APHANET.ORG>; Mica, Alicia Kerry <AMica@APHANET.ORG>
Sent Date:	2020/03/13 15:46:22
Delivered Date:	2020/03/13 15:46:55



March 13, 2020

The Honorable Mike Pence
Vice President
The White House
1600 Pennsylvania Avenue, NW
Washington, DC 20501

RE: APhA Recommendations to the President's Coronavirus Task Force to Maximize the Use of Pharmacists to Prevent, Treat, and Respond to Coronavirus

Dear Vice President Pence:

We are writing to support your efforts and to serve as a resource for the President's Coronavirus Task Force (hereinafter, "Task Force") in assisting both the federal and state governments meet the public health challenges of the coronavirus. APhA has already issued preparedness and prevention guidance for pharmacists, patients and/ or caregivers during the coronavirus pandemic, extending the reach of resources and information provided by Centers for Disease Control ("CDC") and other reputable sources.¹ Pharmacists are well-positioned to provide information and educational resources related to coronavirus to the public. We can do more.

As President Trump has declared a national public health emergency under the National Emergencies Act and the Secretary of Health and Human Services ("HHS") has declared a public health emergency under Section 319 of the Public Health Service Act, the Secretary is authorized to take additional actions in addition to his regular authorities. Under Section 1135 of the Social Security Act, the HHS Secretary may now temporarily waive or modify certain Medicare, Medicaid, and Children's Health Insurance Program ("CHIP") requirements to ensure that sufficient health care items and services are available to meet the needs of individuals enrolled in Social Security Act programs in the emergency area and time periods. It also allows providers who provide such services in good faith can be reimbursed and exempted from sanctions (absent any determination of fraud or abuse). **Accordingly, APhA urges the Task Force and the HHS Secretary to use the full authority of Section 1135 to maximize the use of pharmacists to prevent, treat, and respond to the coronavirus.** America's pharmacists stand ready and able to provide the patient care services necessary to help meet the public health needs created by the spread of the coronavirus (COVID-19).

APhA represents nearly 60,000 pharmacists, pharmaceutical scientists, student pharmacists, pharmacy technicians, and others interested in improving medication use and advancing patient care. APhA members provide care in all practice settings, including community pharmacies, specialty pharmacies, hospitals, long-term care facilities, community health centers, physician offices, ambulatory clinics, managed care organizations, hospice settings, and the uniformed services. APhA has a track record as a strong partner with the Department of Health and Human

¹ APhA Issues Preparedness and Prevention Guidance During Coronavirus Pandemic. Press Release. March 6, 2020, available at: <https://www.pharmacist.com/press-release/apha-issues-preparedness-and-prevention-guidance-during-coronavirus-pandemic>

Services (“HHS”), CDC, Food and Drug Administration (“FDA”) and other agencies in addressing public health needs of communities such as immunizations, emergency preparedness, substance use disorder/opioids, diabetes and other public health concerns.

You recently stated at a Task Force press conference that “...our objective, ultimately, and as quickly as possible, is to have tests made through these commercial laboratories and commercial providers that your local doctor, your CVS, your MedCheck is able to have a coronavirus test. And that isn’t there yet; we’re working to make that a reality.”² You mentioned this again at a coronavirus briefing with diagnostic lab CEOs.³

In several states pharmacists currently have the training and authority to conduct influenza and strep testing, providing either treatment or referral based on the test results.⁴ In addition, more than 360,000 pharmacists have been trained to administer vaccines across the lifespan.⁵ Pharmacists stand ready to help meet your access goal and the needs of our communities as the coronavirus test and vaccine becomes broadly available. Pharmacists are the most accessible health care provider and provide care and services in a wide variety of practice settings in communities across our nation – making them uniquely qualified to reduce clinical burdens and improve patient health. In fact, 90% of all Americans live within five miles of a community pharmacy.⁶ In addition to being medication experts, pharmacists also provide a broad array of services beyond dispensing medications, including disease state and medication management, smoking cessation counseling, health and wellness screenings, preventive services, and immunizations.⁷ Our members are well-situated to work collaboratively with HHS to intervene and provide meaningful services to curb the spread of the coronavirus and play an integral role in containment and mitigation.

To assist patients during this time, APhA supports the Task Force and CMS’ efforts and issuing of guidance to health plans to reduce regulatory and payment barriers for prescription refills, the need for prior authorization, and home delivery. As you likely know, many pharmacies also provide prescription delivery services, which will allow patients to stay at home if clinically advisable, thus minimizing disease transmission.

In addition, APhA offers the following additional immediate actions the Task Force can take to help curb the looming crisis:

1. Allow Pharmacist Administration of the Coronavirus Test as a Rapid Diagnostic Test

The Task Force could expand public access to coronavirus testing through utilization of pharmacists to collect samples according to CDC guidelines for the currently available tests, and submit them to approved labs, interpret and communicate the results to patients, make

² Press Briefing by Vice President Pence and Members of the White House Coronavirus Task Force. March 4, 2020, available at: <https://www.whitehouse.gov/briefings-statements/press-briefing-vice-president-pence-members-white-house-coronavirus-task-force-2/>

³ Remarks by Vice President Pence at a Coronavirus Briefing with Diagnostic Lab CEOs. March 4, 2020, available at: <https://www.whitehouse.gov/briefings-statements/remarks-vice-president-pence-coronavirus-briefing-diagnostic-lab-ceos/>

⁴ NASPA. Pharmacist Prescribing: “Test and Treat.” February 8, 2019, available at: <https://naspa.us/resource/pharmacist-prescribing-for-strep-and-flu-test-and-treat/>

⁵ APhA 2019 Annual Report.

⁶ NCPDP Pharmacy File, ArcGIS Census Tract File. NACDS Economics Department.

⁷ Avalere. Exploring Pharmacists’ Role in a Changing Healthcare Environment. May 21, 2014, available at: <https://avalere.com/insights/exploring-pharmacists-role-in-a-changing-healthcare-environment>

appropriate referrals and guide patients on prevention and appropriate next steps. Once a rapid diagnostic coronavirus test is available for point of care testing, we encourage utilization of pharmacists to assess patients, conduct testing, interpret the results and provide available treatment or referrals, according to CDC guidance. This would align with what pharmacists are currently authorized to do in 17 states for strep throat or influenza.⁸ In Idaho, pharmacists are already authorized to prescribe products to treat strep/flu pursuant to a rapid diagnostic test and using an evidence-based protocol. Florida recently passed a law permitting pharmacists to test for strep, flu and some skin conditions. Beyond statewide authority, many other states have collaborative practice authority (“CPA”) broad enough to allow pharmacists to order or administer laboratory tests pursuant to the terms of the CPA with a prescriber. The Task Force could immediately encourage states to include this authority, if it doesn’t already exist, through Governor declarations or other mechanisms, optimizing the skillset of pharmacists, managing demand, and ultimately allowing primary care practices, emergency rooms, and hospitals to handle more critical patients’ cases.

In addition, once antiviral medications are approved and available to treat individuals with coronavirus, the Task Force should encourage states and payers to recognize and utilize pharmacists in the evaluation of patients and the prescribing of appropriate medications as it currently done in several states with antivirals to treat influenza. With these medications the timely prescribing and use of medications is critical for success.

2. Allow All Pharmacies to Receive a Certificate of Waiver and to Offer the Coronavirus Test as a Clinical Laboratory Improvement Amendments (“CLIA”)-waived Point-of-Care (“POC”) Test

In addition, under Medicare, a pharmacy may possess a CLIA Certificate of Waiver so that they may expand patient access to CLIA-waived tests and improve public health. For example, patients may come to a pharmacy that has a Certificate of Waiver and ask to obtain a CLIA-waived POC test for an infectious disease. One recent study involved pharmacists in three states, where pharmacists in waived pharmacies worked with a physician under a CPA to help identify patients for an influenza POC test and subsequent identification and management of patients who tested positive for influenza.⁹ This model improves identification of patients with infectious conditions earlier, particularly for patients without a primary care provider or who are screened outside of regular clinic office hours and could serve a vital role in assisting to identify patients with the coronavirus and get them to appropriate treatments. Forty-four states allow for pharmacist POC testing for influenza and strep. Accordingly, APhA strongly recommends CMS and the Task Force allow all pharmacies to receive a Certificate of Waiver, when appropriate, for the coronavirus point of care testing when it is available, thereby removing administrative barriers to test access. Offering the coronavirus test as a CLIA-waived point-of-care POC test for an infectious disease would assist the health system and medical providers in triaging patients. CMS should also be certain to ensure that pharmacies and pharmacists are able to recoup both the costs associated with the CLIA-waived coronavirus test and the pharmacist’s time under this model.

⁸ NASPA. Pharmacist Prescribing: “Test and Treat,” February 8, 2019, available at: <https://naspa.us/resource/pharmacist-prescribing-for-strep-and-flu-test-and-treat/>

⁹ ME Klepser, et al. Effectiveness of a pharmacist-physician collaborative program to manage influenza-like illness. J Am Pharm Assoc. 2016; 56:14-21, available at: <https://www.ncbi.nlm.nih.gov/pubmed/26802915>

3. Recognize and Utilize Pharmacists as Capable Vaccine Providers for the Coronavirus Vaccine When Available

Pharmacists are important members of the “immunization neighborhood” and improve patient access to vaccinations recommended by the CDC Advisory Committee on Immunization Practices (“ACIP”) across the lifespan. As a reminder, ACIP and CDC “...defines a health care provider as anyone who provides or administers vaccines: primary care physicians, specialists, physician assistants, nurse practitioners, registered nurses, and pharmacists.”¹⁰ Thanks to changes in state laws, pharmacists are playing an increasingly critical role in increasing influenza-vaccination rates across the United States, with an additional 4.1 million additional adults vaccinated in 2013 because states allowed pharmacists to administer the flu vaccine, which resulted in between 81,000-134,000 fewer influenza infections among adults in that year, depending on vaccine effectiveness. Additionally, the odds that an adult would receive the flu shot increased by 7.8 percent in states that allowed pharmacists to be immunizers.¹¹ In addition to influenza vaccination, pharmacists administer vaccines across the lifespan in accordance with ACIP recommendations, as authorized by state laws and regulations.

The Task Force should encourage and work with states to remove any barriers to pharmacists and other health care professionals’ ability to access and administer coronavirus vaccine when it becomes available. In addition, CMS should require Part D and Medicare Advantage plans to recognize and compensate / reimburse pharmacists as they do physicians and other immunization providers and maximize the inclusion of pharmacists as in-network clinicians to provide the coronavirus vaccine when it becomes available. Furthermore, CMS should remove any barriers for pharmacists to be immunizers of the coronavirus vaccine, when available, whether under Part B or Part D. CMS permits an entity or individual, such as a pharmacist/ pharmacy, who wishes to furnish mass immunization services, but may not otherwise qualify as a Medicare provider, to enroll as a “mass immunizer.” Currently, pharmacies as mass immunizers are restricted from billing Medicare for any services other than pneumococcal pneumonia vaccines (“PPVs”), influenza virus vaccines, and their administration.¹² Accordingly, due to this public health emergency, the Task Force and CMS should immediately act to ease the requirements to become an immunizer and allow pharmacists and pharmacies to meet the demand for distributing the coronavirus vaccine once it becomes available, whether under Part B or Part D. In addition, CMS should require Part D sponsors to submit and CMS to aggregate data from Medicare Advantage (“MA”)-Prescription Drug (“PD”) and Part D plan sponsors to better monitor, measure and attribute the impact different providers, including pharmacists, have on coronavirus vaccination rates of Medicare beneficiaries and encourage private plans to do the same.

4. Remove Administrative Barriers that Impact Pharmacists Delivery of Care for Patient Preparedness

¹⁰ CDC. ACIP Shared Clinical Decision-Making Recommendations. Frequently Asked Questions. Last reviewed: February 10, 2020, available at: <https://www.cdc.gov/vaccines/acip/acip-scdm-faqs.html>

¹¹ Drozd EM, Miller L, Johnsrud M. Impact of Pharmacist Immunization Authority on Seasonal Influenza Immunization Rates Across States. Clin Ther. 2017 Aug 3. pii: S0149-2918(17)30771-3, available at: <https://www.ncbi.nlm.nih.gov/pubmed/28781217>

¹² Centers for Medicare & Medicaid Services (CMS) Internet-only manual (IOM), Publication 100-08, Medicare Program Integrity Manual, Chapter 15, Section 15.4.6.2 -- Mass Immunizers Who Roster Bill. September 29, 2019, available at: <https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/pim83c15pdf.pdf>

On March 12, 2020, APhA called on all of the nation's health insurers and pharmaceutical benefit managers ("PBMs") to immediately remove/waive any administrative barriers on pharmacists and patients for access to early medication refills from their pharmacy of choice to ensure patients have the medications necessary for chronic diseases to address their needs during the ongoing coronavirus pandemic.

We appreciate the steps already taken by some states and payers authorizing pharmacists to dispense emergency refills or waiving early medication refill limits on 30-day prescription maintenance medications, and the guidance in this area issued by the CDC and Department of Homeland Security. APhA also appreciates the recent actions taken by CMS reminding Medicare Advantage and Part D plans of their ability to: 1) remove prior authorization requirements; 2) waive prescription refill limits, and 3) relax the restrictions on home or mail delivery of prescription drugs.

However, the Task Force could ease confusion by implementing uniform measures to ease the burdens on pharmacists and patients across the country. Without immediate changes to implement broad, system-wide authorization for early or emergency refills for chronic medications, patients may have to endure long waits at the pharmacy while the pharmacist addresses the administrative barriers. Not only does this frustrate patients and increase their risks of exposure in public places, but it challenges pharmacists' ability to deliver patient care services.

In addition to all of the above, we urge the Task Force to provide appropriate and effective protective equipment (N-95 masks, gloves, etc.) to pharmacists and other health care professionals providing direct patient care to individuals. This will address a significant concern of providers who are serving the needs of their communities, and at the same time are concerned with spreading coronavirus to their own families. Without the availability of these individuals the system will break down.

Conclusion

Pharmacists stand ready and able to help. We look forward to working the President's Coronavirus Task Force to intervene and provide meaningful services to meet the public health challenge created by the coronavirus – which can serve as an effective mechanism to combat additional public health emergencies in the future. If you have any questions, or if we can be of any assistance, please do not hesitate to contact Michael Baxter, Director of Regulatory Affairs, at mbaxter@aphanet.org or by phone at (202) 429-7538.

Sincerely,



Thomas E. Menighan, BSPHarm, MBA, ScD (Hon), FAPhA
Executive Vice President and CEO

CC: The Honorable Ambassador Dr. Debbie Birx, White House Coronavirus Response Coordinator
The Honorable Alex Azar, Secretary, HHS
Dr. Robert Kadlec, Assistant Secretary for Preparedness and Response, HHS
The Honorable Seema Verma, Administrator, CMS
The Honorable Robert Wilkie, Secretary, Department of Veterans Affairs
The Honorable Dr. Ben Carson, Secretary, Department of Housing and Urban Development
The Honorable Dr. Stephen Hahn, Commissioner, Food and Drug Administration
VADM Dr. Jerome M. Adams, U.S. Surgeon General
Kelvin K. Droegemeier, Director, White House Office of Science and Technology Policy
Robert O'Brien, Assistant to the President for National Security Affairs
Dr. Robert Redfield, Director, CDC
Dr. Anthony Fauci, Director, The National Institute of Allergy and Infectious Diseases at the National Institutes of Health
Deputy Secretary Stephen Biegun, Department of State
Ken Cuccinelli, Acting Deputy Secretary, Department of Homeland Security
Joel Szabat, Acting Under Secretary for Policy, Department of Transportation
Matthew Pottinger, Assistant to the President and Deputy National Security Advisor
Rob Blair, Assistant to the President and Senior Advisor to the Chief of Staff
Joseph Grogan, Assistant to the President and Director of the Domestic Policy Council
Christopher Liddell, Assistant to the President and Deputy Chief of Staff for Policy Coordination
Derek Kan, Executive Associate Director, Office of Management and Budget
Larry Kudlow, Assistant to the President for Economic Policy and Director for National Economic Council
Dr. Anita Patel, Senior Advisor, Pandemic Preparedness and Response, CDC
Mark Meadows, Chief of Staff, The White House